Zhang Alexandra Y, Camp William L, Elewski Boni E
Department of Dermatology, University of Alabama at Birmingham, EFH 414, 1530 3rd Avenue South, Birmingham, AL 35294, USA.
Dermatol Clin. 2007 Apr;25(2):165-83, vi. doi: 10.1016/j.det.2007.01.002.
Topical antifungal agents are generally used for the treatment of superficial fungal infections unless the infection is widespread, involves an extensive area, or is resistant to initial therapy. Systemic antifungals are often reserved for the treatment of onychomycosis, tinea capitis, superficial and systemic candidiasis, and prophylaxis and treatment of invasive fungal infections. With the development of resistant fungi strains and the increased incidence of life-threatening invasive fungal infections in immunocompromised patients, some previously effective traditional antifungal agents are subject to limitations including multidrug interactions, severe adverse effects, and their fungistatic mechanism of actions. Several new antifungal agents have demonstrated significant therapeutic benefits and have broadened clinicians' choices in the treatment of superficial and systemic invasive fungal infections.
局部抗真菌药物通常用于治疗浅表真菌感染，除非感染范围广泛、累及大面积区域或对初始治疗耐药。全身性抗真菌药物通常用于治疗甲癣、头癣、浅表和全身性念珠菌病，以及侵袭性真菌感染的预防和治疗。随着耐药真菌菌株的出现以及免疫功能低下患者中危及生命的侵袭性真菌感染发病率的增加，一些以前有效的传统抗真菌药物受到了限制，包括多药相互作用、严重不良反应及其抑菌作用机制。几种新型抗真菌药物已显示出显著的治疗效果，并拓宽了临床医生在治疗浅表和全身性侵袭性真菌感染方面的选择。
